Panacea Biotec Ltd - Company Profile
Powered by 
All the sales intelligence you need on Panacea Biotec Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Panacea Biotec Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Panacea Biotec Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Panacea Biotec Ltd (Panacea) is engaged in the research, development, manufacturing, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and nutritional products. It also offers contract research and manufacturing services.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Panacea has developed viral, recombinant, sub-unit and polysaccharide conjugate vaccines using both mammalian and bacterial expression platforms. The company has also established a high-cell-density E. coli platform to produce recombinant antigens and proteins, aiding in the development of recombinant molecules for vaccines and therapeutics. Panacea has a state-of-the-art research and development infrastructure, with the One-Stream Research and Development (R&D) Center (ORC) in New Delhi and a vaccine formulation R&D center in Lalru, Punjab, with around 77 scientists. The ORC is responsible for carrying out research activities for developing vaccines using advanced genetic engineering technologies, molecular biology, bacterial culture, animal cell culture, and other modern techniques. The Lalru center focuses on vaccine formulation development and is equipped with the necessary infrastructure and scientific manpower to handle aseptic and blending operations for various vaccines. The company’s R&D capabilities include advanced genetic engineering, molecular biology, bacterial and animal cell cultures, fermentation, purification, and analytical characterization. These facilities are equipped with the necessary infrastructure and scientific expertise to carry out innovative research in antigen design, expression, and immunological evaluation. The pipeline includes products like DengiAll, NuCoVac11, Mpox candidate vaccine, and a multi-epitope nanoparticle-based broadly protective beta coronavirus vaccine candidate. The company collaborates with the Indian Council of Medical Research (ICMR) for clinical trials and has a strong team to develop conjugation chemistries for polysaccharide-based vaccines. In FY2025, the company invested INR315.9 million in R&D, representing 10.2% of its total revenue.
Business Segments
Overview
Operates through its subsidiary Panacea Biotec Pharma Ltd (PBPL). PBPL exports pharmaceutical products to markets across Europe, Asia, Africa, and Latin America. It has a portfolio that spans over 40 countries, including the US, Canada, Germany, UAE, Saudi Arabia, Jordan, Qatar, Turkey, Russian Federation, Kazakhstan, Uzbekistan, Serbia, Tanzania, Kenya, Uganda, Vietnam, Philippines, Thailand, Sri Lanka, Brazil, Panama, Ecuador, Paraguay and Trinidad & Tobago. It focuses on niche therapeutic areas, such as transplantation, oncology, renal disease, pain management, respiratory, diabetes, and gastrointestinal care. PBPL has also entered the nutrition sector, launching its ChilRun product line, which includes pediatric nutrition solutions. These products are available in India and can be found on major e-commerce platforms like Amazon and Tata 1mg.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers pediatric vaccine portfolio that provides critical protection for newborns against diseases like Diphtheria, Tetanus Toxoid, B. Pertussis, Hepatitis B, Hib Type b, and Polio. It has pioneered several vaccines, including the world’s first fully liquid wP-IPV-based hexavalent vaccine (EasySix), the first fully liquid wP-IPV-based pentavalent vaccine (EasyFourPol), and the first fully liquid wP-based pentavalent vaccine (Easyfive-TT). It has also developed the world’s first monovalent oral polio vaccines (mOPVs) and the bivalent oral polio vaccine (Bi-OPV), which targets Poliovirus Types 1 and 3. It is developing a range of innovative vaccines, including DengiAll, a single-dose live-attenuated tetravalent vaccine for dengue fever, NucoVac11, an 11-valent pneumococcal conjugate vaccine, a Hepatitis A vaccine, and a multi-epitope nanoparticle-based vaccine for Betacoronavirus.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer